IP Library › Granted Patent US 10,240,124
Granted Patent B2
US 10,240,124 · App. 14/360,040 · Granted Mar 26, 2019

Cell culture substrate comprising a laminin and a cadherin

Inventors: Karl Tryggvason (Djursholm, SE); Sergey Rodin (Stockholm, SE)
Assignee: BioLamina AB
C12N5/0607C07K14/705C07K14/78C12M25/00C12N5/0068C12N5/0606C12N5/0696C12N2501/115C12N2533/52C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,240,124
App. No.
14/360,040
Granted
Mar 26, 2019
Kind
B2
Abstract

The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with recombinant laminin-521 (laminin-11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.

Claims (16)

1. A method for maintaining stem cells, comprising:

plating the stem cells on a substrate comprising a laminin and a cadherin,

wherein the laminin is an intact protein; and

exposing the stem cells to a cell culture medium comprising at least 0.3 mM of albumin;

wherein the laminin is laminin-521;

wherein the cadherin is e-cadherin; and

wherein the weight ratio of the laminin-521 to the e-cadherin is from 5:1 to 10:1.

2. The method of claim 1 , wherein the cell culture medium is mTeSR1 medium with additional albumin to arrive at an albumin concentration of at least 0.3 mM.

3. The method of claim 1 , wherein the substrate and the medium do not contain any differentiation inhibitors, feeder cells, differentiation inductors, or apoptosis inhibitors.

4. The method of claim 1 , wherein the stem cells are plated at a density of 200 cells/mm 2 or less.

5. The method of claim 1 , wherein the stem cells are plated at a density of 200 cells/mm 2 or more.

6. The method of claim 1 , wherein the stem cells are plated such that no two stem cells contact each other.

7. The method of claim 1 , wherein the cell culture medium is mTeSR1 medium with about 0.39 mM albumin.

8. The method of claim 1 , wherein the albumin is human serum albumin.

9. The method of claim 1 , wherein the human serum albumin is recombinant human serum albumin.

10. The method of claim 1 , wherein the laminin is an effective recombinant laminin.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 5, 2014
From: TRYGGVASON, KARL; RODIN, SERGEY
To: BIOLAMINA AB
Reel/Frame 034394/0880 →
Continuity (6)
Provisional Application 61625321 · Apr 17, 2012
Provisional Application 61624588 · Apr 16, 2012
Provisional Application 61565849 · Dec 1, 2011
Provisional Application 61565380 · Nov 30, 2011
Provisional Application 61537940 · Sep 22, 2011
Related Publication 20140315306A1 · Oct 23, 2014